The company is not selling any securities under this prospectus and will not receive any of the proceeds from the sale of our common shares by the selling shareholder, Armistice Capital Master Fund.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MDCX:
- Is MDCX a Buy, Before Earnings?
- Optimistic Buy Rating for Medicus Pharma Ltd Driven by Promising SkinJect Developments and Strategic Initiatives
- Medicus Pharma Seeks FDA Priority Voucher for Innovative Skin Cancer Treatment
- Medicus Pharma announces filing of CNPV application for SKNJCT-003
- Medicus Pharma Reports Q3 Loss Amid Strategic Growth